CD44 and neoplasm: Similarly, dual CAR-NK cells against CD44-CD24 and CD44–mesothelin illustrated superior killing against triple-negative breast cancer cells, reducing tumor survival to 4–10% compared to 18–25% with single-target CARs [8].